Electromed (ELMD) Competitors

Bioventus (NYSE:BVS) and Electromed (NYSE:ELMD) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, community ranking, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

Does the MarketBeat Community favor BVS or ELMD?

Bioventus received 17 more outperform votes than Electromed when rated by MarketBeat users. However, 86.67% of users gave Electromed an outperform vote while only 63.83% of users gave Bioventus an outperform vote.

Company	Underperform	Outperform
Bioventus	Outperform Votes 30 63.83%	Underperform Votes 17 36.17%
Electromed	Outperform Votes 13 86.67%	Underperform Votes 2 13.33%

Do analysts rate BVS or ELMD?

Bioventus presently has a consensus target price of $13.00, suggesting a potential upside of 11.02%. Given Bioventus' stronger consensus rating and higher probable upside, research analysts clearly believe Bioventus is more favorable than Electromed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Electromed	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Is BVS or ELMD more profitable?

Electromed has a net margin of 11.34% compared to Bioventus' net margin of -7.11%. Bioventus' return on equity of 15.61% beat Electromed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventus	-7.11%	15.61%	4.01%
Electromed	11.34%	15.32%	13.13%

Does the media prefer BVS or ELMD?

In the previous week, Electromed had 2 more articles in the media than Bioventus. MarketBeat recorded 3 mentions for Electromed and 1 mentions for Bioventus. Bioventus' average media sentiment score of 0.90 beat Electromed's score of 0.54 indicating that Bioventus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bioventus	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Electromed	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has better earnings and valuation, BVS or ELMD?

Electromed has lower revenue, but higher earnings than Bioventus. Bioventus is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$512.34M	1.85	-$156.23M	-$0.61	-19.20
Electromed	$57.06M	4.41	$5.15M	$0.72	41.35

Which has more volatility and risk, BVS or ELMD?

Bioventus has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500. Comparatively, Electromed has a beta of 0.27, suggesting that its stock price is 73% less volatile than the S&P 500.

Do insiders & institutionals have more ownership in BVS or ELMD?

62.9% of Bioventus shares are owned by institutional investors. Comparatively, 40.8% of Electromed shares are owned by institutional investors. 32.9% of Bioventus shares are owned by insiders. Comparatively, 14.0% of Electromed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Bioventus beats Electromed on 10 of the 18 factors compared between the two stocks.